GleamWall
中文EN

ZVRA ZEVRA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1434647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY75.1%
TTM net income YoY120.8%
TTM EPS YoY159.6%
Revenue 3-yr CAGR106.2%
Net income 3-yr CAGR—

Margins

Gross margin95.4%
Operating margin60.8%
Net margin52.8%
FCF margin25.9%
EBITDA margin61.8%

Returns

ROE41.9%
ROA26.7%
ROIC (approx.)60.6%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio5.46x
Interest coverage24.55x

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio13.5%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$37.76M$39.66M$36.22M$34.12M$26.06M$25.88M$20.40M$12.04M
Cost of revenue$1.79M$1.52M$1.90M$1.52M$1.24M$12.38M$1.34M$1.37M
Gross profit$35.96M$38.14M$34.32M$32.60M$24.82M$13.50M$19.06M$10.68M
R&D expense$4.94M$4.49M$4.39M$2.62M$3.43M$3.43M$3.26M$8.35M
SG&A expense$19.13M$16.56M$20.78M$20.35M$16.93M$20.78M$19.55M$16.12M
Operating income$11.58M$16.78M$52.15M$9.31M$4.14M-$71.04M-$5.36M-$15.42M
Interest expense$0$0$1.71M$1.95M$2.05M$2.01M$1.97M$2.19M
Pretax income$19.72M$12.79M$44.80M$12.67M-$977,000$76.91M-$1.92M-$20.37M
Income tax$510,000$4.04M$6.91M$501,000-$433,000$2.20M$1.18M$15.37M
Net income$19.21M$8.75M$37.89M$12.16M-$544,000$74.71M-$3.10M-$35.74M
EBITDA$11.96M$17.14M$52.51M$9.68M$4.54M-$69.39M-$3.71M-$13.77M
EPS (basic)0.310.140.62—-0.011.24-0.06—
EPS (diluted)0.260.140.60—-0.011.21-0.06—
Weighted avg. shares (diluted)61.73M61.34M60.23M—55.95M56.32M54.10M—
Balance sheet
Cash & equivalents$122.15M$145.32M$95.59M$62.41M$54.44M$47.71M$37.34M$33.78M
Short-term investments$73.42M$76.25M$105.02M$128.60M$145.07M$154.90M$25.29M$35.71M
Receivables———————$10.18M
Inventory$3.07M$2.45M$2.31M$1.74M$1.37M$1.11M$2.56M$1.97M
Current assets$225.84M$251.30M$229.97M$223.01M$225.12M$226.34M$81.57M$86.03M
PP&E, net$816,000$641,000$430,000$489,000$488,000$599,000$422,000$356,000
Goodwill$4.70M$4.70M$4.70M$4.70M$4.70M$4.70M$4.70M$4.70M
Intangibles$5.47M$5.79M$6.11M$6.42M$6.74M$7.05M$67.38M$68.99M
Total assets$313.57M$302.71M$278.58M$284.73M$270.12M$256.28M$172.71M$178.13M
Current liabilities$41.37M$48.63M$47.03M$39.28M$26.11M$28.83M$26.98M$34.06M
Long-term debt$0$0$0$61.93M$61.31M$60.69M$60.09M$59.50M
Total debt$0$0$0$61.93M$61.31M$60.69M$60.09M$59.50M
Total liabilities$74.65M$85.06M$72.78M$130.07M$136.95M$139.05M$131.69M$138.46M
Shareholders' equity$238.92M$217.65M$205.80M$154.66M$133.16M$117.23M$41.02M$39.67M
Net debt-$122.15M-$145.32M-$95.59M-$478,000$6.87M$12.98M$22.75M$25.72M
Shares outstanding59.44M59.34M59.11M56.85M56.22M55.08M54.68M53.67M
Cash flow statement
Operating cash flow$10.05M$17.03M$6.14M$5.52M$4.71M-$3.60M-$8.22M-$16.25M
Capital expenditure$238,000$217,000$35,000-$31,000$554,000$213,000$99,000$0
Free cash flow$9.81M$16.82M$6.11M$5.55M$4.16M-$3.81M-$8.32M-$16.25M
Investing cash flow-$34.85M$31.45M$79.62M$227,000-$4.58M$11.93M$10.54M-$5.47M
Financing cash flow$1.55M$1.58M-$52.80M$2.55M$6.53M$1.38M$1.61M$796,000
Depreciation & amortization$378,000$364,000$368,000$362,000$392,000$1.65M$1.65M$1.65M
Stock-based compensation$2.67M$2.97M$3.10M$4.28M$2.77M$2.46M$3.12M$4.02M
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 52 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.